1
|
Werner RN, Pennitz A, Eisert L, Schmidle P, Zink A, Abraham S, Schäkel K, Wolff I, Goebeler M, Plange J, Sollfrank L, Zielbauer S, Koll P, Amschler K, Müller V, Nast A. The impact of off-label use regulations on patient care in dermatology - A prospective study of cost-coverage applications filed by tertiary dermatology clinics throughout Germany. J Eur Acad Dermatol Venereol 2022; 36:2241-2249. [PMID: 35737866 DOI: 10.1111/jdv.18357] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2021] [Accepted: 05/18/2022] [Indexed: 11/29/2022]
Abstract
BACKGROUND In dermatology, a medical specialty with a relatively high number of rare diseases, physicians often have to resort to off-label treatment options. To avoid claims, physicians in Germany can file a cost coverage-request (off label-application, OL-A). OBJECTIVES Our aim was to investigate the extent to which the current regulations affect patient care. MATERIAL AND METHODS Prospective cohort study among tertiary dermatology clinics throughout Germany, consecutively including OL-As (05/2019-09/2020) and assessing the follow-up correspondence. We modelled regressions to assess factors associated with cost coverage decisions and the time needed by health insurers to process the OL-As. RESULTS Thirteen clinics provided data on 121 OL-As, two of which applied for on-label treatments. Of the remaining 119 OL-As, 70 (58.8%) were immediately approved and 44 (37.0%) rejected. Including cases with one or more appeals, 87 of 119 OL-As (73.1%) were finally approved and 26 (21.9%) rejected. There was an association of the final approval rate with (1) the class of medication/treatment, with approval rates being significantly lower for JAK inhibitors than for biologics (OR 0.16, 95%-CI: 0.03-0.82); (2) German state, with approval rates being lower in eastern than in western states (OR 0.30, 95%-CI 0.12-0.76); and (3) cost of the intervention (no linear trend). However, none of these predictors was significant in our multiple logistic regression models. The median health insurer's processing time (first response) was 29 days (IQR 22-38). Our analyses showed no evidence of an association with the predictors we assessed. In cases approved, the median time from the decision to file an OL-A to the actual initiation of the treatment was 65.5 days (IQR 51-92). CONCLUSIONS Our study points to substantial delays and inequalities in the provision of timely health care for dermatological patients with rare diseases, often involving treatments for which there is no adequate approved therapy.
Collapse
Affiliation(s)
- Ricardo Niklas Werner
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Dermatology, Venereology and Allergology, Division of Evidence-based Medicine (dEBM), Charitéplatz 1, 10117, Berlin, Germany
| | - Antonia Pennitz
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Dermatology, Venereology and Allergology, Division of Evidence-based Medicine (dEBM), Charitéplatz 1, 10117, Berlin, Germany
| | - Lisa Eisert
- Vivantes Klinikum Neukölln, Department of Dermatology and Venereology, Rudower Straße 48, 12351, Berlin, Germany
| | - Paul Schmidle
- Technical University Munich, School of Medicine, Department of Dermatology and Allergy Biederstein, Biedersteiner Str. 29, 80802, Munich, Germany
| | - Alexander Zink
- Technical University Munich, School of Medicine, Department of Dermatology and Allergy Biederstein, Biedersteiner Str. 29, 80802, Munich, Germany
| | - Susanne Abraham
- Technische Universität Dresden, Carl Gustav Carus Faculty of Medicine, Department of Dermatology, Fetscherstr. 74, 01307, Dresden, Germany
| | - Knut Schäkel
- University Hospital Heidelberg, Department of Dermatology, Im Neuenheimer Feld 440, 69120, Heidelberg, Germany
| | - Isabel Wolff
- Universitätsklinikum Tübingen, Department of Dermatology, Liebermeisterstraße 25, 72076, Tübingen, Germany
| | - Matthias Goebeler
- Universitätsklinikum Würzburg, Department of Dermatology, Venereology and Allergology, Josef-Schneider Str. 2, Gebäude D8, 97080, Würzburg, Germany
| | - Johanna Plange
- RWTH Aachen University, Department of Dermatology, Pauwelsstrasse 30, 52074, Aachen, Germany
| | - Lukas Sollfrank
- Friedrich Alexander University Erlangen-Nürnberg (FAU), Universitätsklinikum Erlangen, Department of Dermatology, German Center for Immunotherapy, Deutsches Zentrum Immuntherapie, Ulmenweg 20, 91054, Erlangen, Germany
| | - Sebastian Zielbauer
- Goethe Universität Frankfurt am Main, Universitätsklinikum Frankfurt, Department of Dermatology, Venereology and Allergology, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany.,Goethe Universität Frankfurt am Main, Universitätsklinikum Frankfurt, Institute for General Practice, Evidence-based Medicine Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany
| | - Philipp Koll
- Universität zu Köln, Department of Dermatology, Kerpenerstr. 62, 50937, Köln, Germany
| | - Katharina Amschler
- University Medical Center Göttingen, Department of Dermatology, Robert-Koch-Str. 40, 37075, Göttingen, Germany
| | - Verena Müller
- German Cancer Research Center (DKFZ), Skin Cancer Unit, Im Neuenheimer Feld 280, 69120, Heidelberg, Germany.,Ruprecht-Karl University of Heidelberg, Mannheim, University Medical Center Mannheim, Department of Dermatology, Venereology and Allergology, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany
| | - Alexander Nast
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Dermatology, Venereology and Allergology, Division of Evidence-based Medicine (dEBM), Charitéplatz 1, 10117, Berlin, Germany
| |
Collapse
|
2
|
Ständer S, Zeidler C, Magnolo N, Raap U, Mettang T, Kremer AE, Weisshaar E, Augustin M. Clinical management of pruritus. J Dtsch Dermatol Ges 2016; 13:101-15; quiz 116. [PMID: 25631127 DOI: 10.1111/ddg.12522] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The care of patients with chronic pruritus as a symptom of a wide variety of underlying diseases continues to confront dermatologists with diagnostic and therapeutic challenges. However, a structured history and a physical examination may already substantially help in narrowing down the number of potential differential diagnoses. Apart form reducing the intensity of pruritus, identification and appropriate treatment of the underlying disease are important needs of patients. If these goals doesn't lead to improvement of itch, current guidelines provide a number of topical and systemic therapies for symptomatic treatment. Various skin lesions (for example, xerosis caused by irritant substances, secondary scratch lesions) prompt patients to consult a dermatologist, but most cases require an interdisciplinary therapeutic approach to identify potential internal medicine, neurologic, or psychosomatic aspects. Although great strides have been made in basic research, specific therapies are still rare, and a precise knowledge of the legal framework for the implementation of guidelines (for example, off-label use) is essential. This CME article gives an overview of the causes of and treatment options for chronic pruritus and discusses both advances in basic research as well as progress in clinical knowledge.
Collapse
Affiliation(s)
- Sonja Ständer
- Competence Center Chronic Pruritus, Department of Dermatology, University Hospital Muenster, Germany
| | | | | | | | | | | | | | | |
Collapse
|